Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens: Evidence for accumulation of tacrine in brain tissue

Drug Metabolism and Disposition

Volumn 24, Issue 6, 1996, Pages 628-633

  McNally, William P ^a   Pool, William F ^a   Sinz, Michael W ^a   Dehart, Peter ^a   Ortwine, Daniel F ^a   Huang, Che C ^a   Chang, Tsun ^a   Woolf, Thomas F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TACRINE; TACRINE DERIVATIVE; VELNACRINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BRAIN HOMOGENATE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CHOLINESTERASE INHIBITORS; MALE; RATS; RATS, WISTAR; TACRINE; TISSUE DISTRIBUTION;

EID: 0029898842     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. M. J. Knapp, D. S. Knopman, P. R. Soloman, W. W. Pendlebury, C. S. Davis, and S. I. Gracon: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J.A.M.A. 271, 985-991 (1994).
2. S. I. Gracon, T. M. Hoover, K. W. Lewis, J. Dolan-Ureno, M. M. Rieger, S. L. Myers, and M. J. Knapp: Tacrine in Alzheimer's disease: efficacy and safety in a parallel-group study. In "Alzheimer's Disease: Advances in Clinical and Basic Research" (B. Corain, K. Iqbal, M. Nicolini, B. Winblad, H. Wisniewski, and P. Zatta, eds.), pp. 551-557. Wiley, New York, 1993.
3. M. Farlow, S. I. Gracon, L. A. Hershey, K. W. Lewis, C. H. Sadowsky, and J. Eolan-Ureno: A controlled trial of tacrine in Alzheimer's disease. J.A.M.A. 268, 2523-2529 (1992).
4. M. J. Knapp, S. I. Gracon, C. S. Davis, P. R. Solomon, W. W. Pendlebury, and D. S. Knopman: Efficacy and safety of high-dose tacrine: a 30-week evaluation, Alzheimer Dis. Assoc. Disord. 8 (Suppl. 20), S22-31 (1994).
5. R. J. Baldessarini: Drugs and the treatment of psychiatric disorders. In "The Pharmacological Basis of Therapeutics" (A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor, eds.), 8th ed., pp. 383-462. Pergamon Press, New York, 1990.
6. W. McNally, M. Roth, R. Young, H. Bockbrader, and T. Chang: Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose. Pharm. Res. 6, 924-930 (1989).
7. W. P. McNally, P. DeHart, W. Pool, and T. Chang: A comparison of in vivo distribution of radioactivity in rat brain following oral administration of tacrine or its 1-hydroxy metabolite. Soc. Neurosci. 17, 274.12 (abstr.) (1991).
8. V. E. Gregor, M. R. Emmerling, C. Lee, and C. J. Moore: The synthesis and in vitro acetylcholinesterase and butyrlcholinesterase inhibitory activity of tacrine (Cognex®) derivatives. Bioorg. Med. Chem. Lett. 2, 861-864 (1992).
9. G. M. Shutske, F. A. Pierrat, K. J. Kapples, M. L. Cornfeldt, M. R. Szewczak, F. P. Huger, G. M. Bores, V. Haroutunian, and K. L. Davis: 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. J. Med. Chem. 32, 1805-1813 (1989).
10. G. M. Shutske, F. A. Pierrat, M. L. Cornfeldt, M. R. Szewczak, F. P. Huger, G. M. Bores, V. Haroutunian, and K. L. Davis: (±)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. J. Med. Chem. 31, 1278-1279 (1988).
11. T. F. Woolf, W. F. Pool, S. M. Bjorge, T. Chang, O. P. Goel, C. F. Purchase II, M. C. Schroeder, K. L. Kunze, and W. F. Trager: Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations: species difference. Drug Metab. Dispos. 21, 874-882 (1993).
12. R. Katzman: Alzheimer's disease. N. Engl. J. Med. 314, 964-973 (1986).
13. R. S. Hsu, G. M. Shutske, E. M. Dileo, S. M. Chesson, A. R. Linville, and R. C. Allen: Identification of the urinary metabolites of tacrine in the rat. Drug Metab. Dispos. 18, 779-783 (1990).
14. J. A. Nielsen, E. E. Mena, I. H. Williams, M. R. Nocerini, and D. Liston: Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur. J. Pharmacol. 173, 53-64 (1989).
15. H. A. Baldwin, R. J. De Souza, G. S. Sarna, T. K. Murray, A. R. Green, and A. J. Cross: Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses. Br. J. Pharmacol. 103, 1946-1950 (1991).
16. M. Telting-Diaz and C. E. Lunte: Distribution of tacrine across the bloodbrain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharm. Res. 10, 44-48 (1993).